Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Type of study
Language
Publication year range
2.
Pediatr Dermatol ; 41(1): 139-140, 2024.
Article in English | MEDLINE | ID: mdl-37495552

ABSTRACT

Atopic dermatitis (AD) is predominantly mediated by a T-helper 2 immune system response. While JAK inhibitors have gained treatment approval for AD, data regarding interclass efficacy and therapeutic rationale is lacking. We report a patient with recalcitrant AD who failed baricitinib but demonstrated an excellent response to the pan-JAK inhibitor tofacitinib.


Subject(s)
Azetidines , Dermatitis, Atopic , Janus Kinase Inhibitors , Purines , Pyrazoles , Pyrimidines , Sulfonamides , Humans , Janus Kinase Inhibitors/therapeutic use , Dermatitis, Atopic/drug therapy , Piperidines/therapeutic use , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...